+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 66 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effects of NB-4746 compared with placebo in adults with amyotrophic lateral sclerosis ALS. This trial aims to understand the safety, side effects, how NB-4746 moves through the body, and changes in a blood marker called neurofilament light NfL, which indicates nerve cell damage. The study is divided into two parts and includes an optional open-label extension. In Part A, participants are randomly assigned to receive either a low dose of NB-4746, a high dose of NB-4746, or placebo capsules taken twice daily for about one month. In Part B, participants are again randomized to receive NB-4746 at a dose determined based on Part A results or placebo capsules twice daily for about twelve weeks. After completing Part A or B, participants may opt to continue treatment in an open-label extension lasting up to one year. Participants will be monitored throughout the trial with regular health checks focusing on ALS symptoms and overall wellbeing. Researchers will track adverse events, measure blood levels of NB-4746, and assess changes in neurofilament light to evaluate nerve damage. Safety and tolerability will be evaluated from enrollment through the treatment periods, with ongoing monitoring during the extension phase.

Age: 18Years - 80YearsAll GendersPhase 1Phase 2
12 locations
O

Actively Recruiting

Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.

Age: 18Years +All GendersPhase 1Phase 2
114 locations
L

Actively Recruiting

Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.

Age: 18Years +All GendersPhase 3
118 locations
P

Actively Recruiting

Researchers are conducting a Phase 12a clinical trial to evaluate the safety and tolerability of DB-1311BNT324 in adults with advanced solid tumors that have progressed after standard treatments or have no available standard options. The trial aims to find the maximum tolerated dose and recommended dose for further study, as well as explore preliminary antitumor activity in selected cancers including prostate cancer. The study is multicenter, open-label, and includes a drug-drug interaction sub-study to assess the effects of other medications on DB-1311. In Phase 1, participants receive escalating single doses of DB-1311BNT324 every three weeks to determine safety and optimal dosing. Phase 2a expands dosing to confirm safety and explore effectiveness of DB-1311 given alone or combined with hormone therapies such as enzalutamide or abiraterone in prostate cancer. Treatment cycles are repeated every 21 days via intravenous infusion. Some participants receive additional oral medications to study interactions. The trial includes various cohorts with different tumor types and prior treatment histories. Participants undergo multiple assessments including safety labs, vital signs, ECGs, heart function tests, and performance status evaluations throughout treatment and for about one year after. Tumor response is measured using standard criteria, along with pharmacokinetic and immunogenicity tests. Researchers monitor adverse events and serious events continuously. The total participation lasts up to approximately one year post-treatment to evaluate safety, dosing, and preliminary outcomes.

Age: 18Years +All GendersPhase 1Phase 2
107 locations
P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
P

Actively Recruiting

This trial focuses on elderly patients aged 80 years or older, or those 75 years and older who are considered frail, with untreated diffuse large B-cell lymphoma DLBCL and related lymphoma subtypes. The study is a phase III, randomized, open-label, multicenter trial conducted in several countries including Sweden, Norway, Finland, Denmark, Italy, Australia, and New Zealand. It aims to compare the standard chemotherapy regimen R-miniCHOP with an experimental treatment R-pola-miniCHP, where vincristine is replaced by polatuzumab vedotin, to assess differences in outcomes for this patient population. Participants will be randomly assigned to one of two treatment groups. One group will receive R-mini-CHOP consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone over six 21-day cycles. The other group will receive R-pola-mini-CHP, which includes rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin instead of vincristine, also given over six 21-day cycles. Both treatments last approximately 18 weeks. The study includes a screening period lasting up to 4 weeks before treatment begins. During the study, participants will be followed for up to 36 months after completing treatment to monitor progression-free survival over two years. Researchers will evaluate disease progression and safety outcomes through regular assessments during and after the treatment period. Participants will provide informed consent and undergo evaluations including health status and disease measurements to ensure eligibility and monitor treatment effects throughout the trial.

Age: 75Years +All GendersPhase 3
69 locations
P

Actively Recruiting

Researchers are evaluating a potential new medicine called CDR132L to understand its effects on the structure and function of the heart in people living with heart failure. The study focuses on participants with heart failure who have reduced or mildly reduced ejection fraction and left ventricular hypertrophy. This research is a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial aiming to assess safety and efficacy in this population. Participants will receive an intravenous infusion of either CDR132L or a placebo once every four weeks for 48 weeks. Alongside this, all participants will continue their individually tailored guideline-directed standard of care therapy for heart failure. The studys main phase covers these 48 weeks of treatment, followed by monitoring adverse events up to week 60. During the approximately 60-week study, participants undergo evaluations including echocardiography and blood tests measuring biomarkers like microRNA-132-3p and NT-proBNP. Researchers will track changes in heart structure and function, adverse events, and safety throughout the study. The primary outcome focuses on changes in normalized microRNA-132-3p levels from baseline to week 24, while secondary outcomes include measures of heart volume and biomarkers, plus adverse event counts.

Age: 40Years - 84YearsAll GendersPhase 2
92 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
E

Actively Recruiting

Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.

Age: 18Years +All GendersPhase 3
210 locations
P

Actively Recruiting

This trial is investigating whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome CRS in people with relapsed or refractory multiple myeloma. CRS is a sudden inflammatory reaction that can cause flu-like symptoms such as fever and tiredness during treatment. The study is a Phase 2, randomized, double-blind, placebo-controlled trial focused on prevention of CRS. Participants will be randomly assigned to receive either tocilizumab plus ramantamig or placebo plus ramantamig. Ramantamig is given as a subcutaneous injection for a finite duration or until the disease progresses or side effects become intolerable. Tocilizumab or placebo is administered as an intravenous injection before ramantamig treatment starts. Two groups are compared one receiving tocilizumab with ramantamig and the other receiving placebo with ramantamig. During the study, participants will be monitored for CRS symptoms and treatment responses up to 38 months. Researchers will assess the percentage of participants alive and free from significant CRS within 28 days after the first dose of ramantamig. Other measures include response rates, duration of response, progression-free survival, and adverse events. Laboratory tests, clinical exams, and safety monitoring are conducted regularly to evaluate the effects and side effects of the treatments.

Age: 18Years +All GendersPhase 2
60 locations

1-10 of 66

1